Rick Kendall
About Rick Kendall
Rick Kendall is the Chief Scientific Officer with a PhD from the University of California, Irvine, and a Bachelor's degree from UCLA. He has held leadership roles at ImmPACT BIO, Kite Pharma, and Amgen, contributing to significant advancements in oncology research.
Title
Rick Kendall is the Chief Scientific Officer. He holds extensive experience in the biotechnology industry, specializing in oncology research and cell therapy.
Education and Expertise
Rick Kendall earned his PhD from the University of California, Irvine, School of Medicine. He obtained his Bachelor of Science degree from the University of California, Los Angeles. His academic background is rooted in rigorous scientific training, which has equipped him with the expertise needed for his roles in biotechnology research and development.
Professional Background
Rick Kendall served as the president and CEO of ImmPACT BIO, a cell therapy company recognized for its innovative contributions to cancer treatment. Additionally, he held the position of vice president of research at Kite Pharma, where he contributed to pivotal oncology research initiatives. At Amgen, he worked as an executive director and head of oncology research, where he played a critical role in advancing cancer therapies.
Notable Achievements in Biotechnology
Rick Kendall has been instrumental in several key projects within the biotechnology field. He initiated efforts that led to the development of LUMAKRAS, the first true KRAS inhibitor, marking a significant breakthrough in cancer treatment. Furthermore, he led the research diligence and integration team for the acquisition of Micromet by Amgen, demonstrating his capability in navigating complex mergers and acquisitions.